Endocrine Today

12/16/2025

Continuous glucose monitoring may have a role in identifying and preventing diabetes among healthy adults, but more studies in people without diabetes need to be conducted, according to a speaker at

https://www.healio.com/news/endocrinology/20251216/cgm-may-be-beneficial-for-people-without-diabetes-but-more-research-needed

Continuous glucose monitoring may have a role in identifying and preventing diabetes among healthy adults, but more studies in people without diabetes need to be conducted, according to a speaker. Viral N. Shah, MD, professor of medicine in the division of endocrinology and metabolism and director o...

12/15/2025

🕎Happy Hanukkah from your friends at Healio! May each night bring you light, love and joy.

12/13/2025

Smarter CME starts here. 💡

Tap in and level up your learning: https://bit.ly/3X9ybIq

12/13/2025

📰 Did you miss out on ? No worries, we’ve got you covered. Catch the meeting highlights here: http://bit.ly/4lX8ntn

Healio is a proud Media Partner of WCIRDC

12/12/2025

💉 A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced greater weight loss than semaglutide alone in a phase 2 trial.

Learn more about nimacimab ⬇️

ATLANTA — A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults with overweight or obesity with no safety concerns, according to data from the CBeyond phase 2a trial. Louis J. Aronne, MD, DABOM, FTOS, the Sanford I. Weill Pro...

12/11/2025

🚨 An investigational triple receptor agonist conferred significant weight loss and reductions in knee osteoarthritis pain in a phase 3 trial, according to topline results from Eli Lilly.

Learn more about retatrutide and the TRIUMPH-4 trial ⬇️

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with overweight or obesity and knee osteoarthritis, according to topline results from the TRIUMPH-4 trial. Retatrutide (Eli Lilly) is a once-weekly injectable GIP/GLP-1/glucagon triple....

12/11/2025

💉 Using a for type 2 or treatment may not affect one’s risk for .
Read our full breakdown of this recently published research in 👇



https://www.healio.com/news/endocrinology/20251209/glp1s-not-tied-to-increased-risk-for-obesityrelated-cancers

12/10/2025

✅ The right answer at the right time = better patient care.
Healio’s Drug Lookup helps you focus less on searching and more on treating. Try Healio’s Drug Lookup now ➡️ https://www.healio.com/clinical-guidance/drugs

12/09/2025

🚨Adults who received for type 2 or in a randomized controlled trial had similar risk for as those receiving placebo, according to new findings published in .
Learn more 👇

https://www.healio.com/news/endocrinology/20251209/glp1s-not-tied-to-increased-risk-for-obesityrelated-cancers

Adults with type 2 diabetes or overweight or obesity who received GLP-1s do not have increased risk for obesity-related cancers, according to findings from a systematic review and meta-analysis published in Annals of Internal Medicine.“Clinically, these findings support the overall safety of G...

12/08/2025

📖The American Diabetes Association 2026 Standards of Care was released today and featured several new and revised recommendations spanning several areas of diabetes care.

Get a rundown of some of the biggest changes ⬇️

New recommendations on glycemic management for people with cancer, continuous glucose monitoring and the use of glucose-lowering therapies are among the biggest updates in the American Diabetes Association’s 2026 Standards of Care.The ADA released its annual Standards of Care on Dec. 8. The do...

12/08/2025

🚨FDA has cleared an updated algorithm for the Omnipod 5 that will allow people with diabetes to set a target glucose as low as 100 mg/dL.

Learn more about the new algorithm ⬇️

The FDA cleared an updated algorithm for a hybrid closed-loop insulin delivery system that permits users to set a lower target glucose, Insulet announced. As Healio previously reported, the FDA approved the Omnipod 5 (Insulet) as the first tubeless hybrid-closed loop insulin delivery system for peop...

12/05/2025

In a world chasing speed, Healio AI delivers what matters most — credibility. 🌟
It’s physician-first AI that transforms information overload into insight.
Built on 1️⃣2️⃣5️⃣ years of trust.
Built for those who Never Settle.

Try it today > Healio.com/AI